Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource, 1 online resource.

Language: Englisch

Bibliographic citation: Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review ; volume:22 ; number:1 ; day:29 ; month:4 ; year:2023 ; pages:1-10 ; date:12.2023
Cardiovascular diabetology ; 22, Heft 1 (29.4.2023), 1-10, 12.2023

Creator: Hoehlschen, Julia
Hofreither, Dominik
Tomin, Tamara
Birner-Grünberger, Ruth

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12933-023-01822-7

URN: urn:nbn:de:101:1-2023090510442503711586

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hoehlschen, Julia
Hofreither, Dominik
Tomin, Tamara
Birner-Grünberger, Ruth
SpringerLink (Online service)

Other Objects (12)

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

Hochschulschrift

The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose-transport independent, but redox-dependent mechanisms

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

Hochschulschrift

The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose-transport independent, but redox-dependent mechanisms

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

Hochschulschrift

The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose-transport independent, but redox-dependent mechanisms

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose-transport independent, but redox-dependent mechanisms

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose-transport independent, but redox-dependent mechanisms

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose-transport independent, but redox-dependent mechanisms

Related objects

Reset password